Greenwich Lifesciences Inc Market Cap ($226.78 Million)
Market Cap & Net Worth: Greenwich Lifesciences Inc (GLSI)
Greenwich Lifesciences Inc market cap. Greenwich Lifesciences Inc (NASDAQ:GLSI) has a market capitalization of $226.78 Million ($226.78 Million) as of November 4, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #15866 globally and #3787 in its home market, demonstrating a -7.04% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Greenwich Lifesciences Inc's stock price $15.92 by its total outstanding shares 14678208 (14.68 Million). Also see GLSI cash flow metrics for how efficiently the company converts equity into cash flow.
Greenwich Lifesciences Inc Market Cap History (2020–2026)
Greenwich Lifesciences Inc market cap history from 2020 to 2026. Data shows growth from $535.31 Million to $233.68 Million (20.87% CAGR). Check GLSI stock price and chart for real-time trading data and today's change.
Index Memberships
Greenwich Lifesciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.01% | #425 of 976 |
|
NASDAQ Composite
IXIC
|
$40.20 Trillion | 0.00% | #1554 of 3165 |
Weight: Greenwich Lifesciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Greenwich Lifesciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Greenwich Lifesciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Greenwich Lifesciences Inc to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of GLSI by Market Capitalization
Companies near Greenwich Lifesciences Inc in the global market cap rankings as of November 4, 2026. Also see GLSI asset base for a full breakdown of the balance sheet.
Key companies related to Greenwich Lifesciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Greenwich Lifesciences Inc (2020–2026)
Market capitalization of Greenwich Lifesciences Inc from 2020 to today. Between 2020 and today, Greenwich Lifesciences Inc's market cap moved from $535.31 Million to $ 233.68 Million, with a yearly change of 20.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $233.68 Million | -24.23% |
| 2025 | $308.39 Million | +87.09% |
| 2024 | $164.84 Million | +6.75% |
| 2023 | $154.41 Million | -30.79% |
| 2022 | $223.11 Million | -37.53% |
| 2021 | $357.12 Million | -33.29% |
| 2020 | $535.31 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Greenwich Lifesciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $226.78 Million USD |
| MoneyControl | $226.78 Million USD |
| MarketWatch | $226.78 Million USD |
| marketcap.company | $226.78 Million USD |
| Reuters | $226.78 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients. The company also develops FLAMINGO-01, which is in Ph… Read more